Control of estrogenic activity within the uterus is evident as unopposed estrogen action is associated with endometrial pathologies such as endometriosis and endometrial carcinoma. MicroRNAs (miRNAs) have emerged as important posttranscriptional regulators, which are postulated to fine-tune the actions of steroids in many systems including the uterus. The objective of the current study was to examine uterine expression of miRNAs in response to estrogen treatment within the mouse uterus using an ovariectomized, steroid-reconstituted mouse model. MicroRNA microarray analysis and subsequent quantitative real-time reverse transcriptase polymerase chain reaction (qRT-PCR) verification revealed that expression of mirn155, mirn429, and mirn451 was significantly increased by estrogen administration whereas mirn181b and mirn204 expression was significantly reduced. Pretreatment with the estrogen receptor (ER) antagonist ICI 182,780 confirmed that estrogen regulation was mediated via the classical ER pathway. This study demonstrates that estrogen regulates specific miRNAs within the murine uterus, which may participate in posttranscriptional regulation of estrogen-regulated genes.
Introduction
The female sex hormone estrogen regulates diverse biological processes that include bone metabolism, cardiovascular functions, developmental processes, and reproductive events. 1 Estrogen action on the uterus is biphasic and can be divided into early and late responses. Early response events include increased RNA transcription, hyperemia, and water imbibition, whereas late events include DNA synthesis and mitosis of epithelium. 2 Estrogen-regulated genes involved in growth factor signaling, Wnt signaling, cell cycle progression, and apoptosis have been associated with these early and late estrogenic responses within the uterus. Regulation of these estrogenic events has been shown to occur via both estrogen receptors (ER)-a and ER-b 3 as well as through alternative estrogensignaling pathways. 2, [4] [5] [6] Understanding the molecular mechanisms that contribute to the development and subsequent function of the uterus are absolutely essential for successful reproduction and/or adequate treatment of uterine disorders that impede the reproductive process. As suggested above, it is well established that numerous estrogen-regulated factors (cytokines, growth factors, steroids, etc) dictate the normal pattern of uterine development and that disruption of the normal action of these factors plays a causative role in uterine abnormalities and infertility. It is becoming increasingly clear that posttranscriptional regulation of such factors may also affect organ development.
As such, developing a thorough understanding of the factors that regulate uterine development and function is of paramount importance within the context of reproductive biology.
MicroRNAs (miRNAs) are a family of small (19-22 nucleotides) noncoding RNAs that are involved in posttranscriptional gene regulation by affecting messenger RNA (mRNA) translation and/or stability. 7, 8 MicroRNA posttranscriptional regulation of specific gene products has been proposed to play a role in the normal development of the lung, 9 limbs, 10 and skeletal muscle 11 as well as the female germ line 12 and female reproductive tract. [13] [14] [15] Recently, posttranscriptional regulation of gene expression by miRNAs has been proposed to play a role in the normal physiology of the human endometrium. [16] [17] [18] Furthermore, studies in rodents have identified specific miR-NAs within the uterus, which are proposed to participate in the preparation of the uterus for embryo implantation. [19] [20] [21] Although there is limited information on the role of miRNAs in normal uterine physiology, there has been a greater emphasis on studying the role of miRNAs in endometrial diseases, which are associated with enhanced or unopposed estrogen responsiveness such as endometriosis [22] [23] [24] [25] [26] and endometrial cancer. [27] [28] [29] Collectively, these studies suggest that miRNAs play a pivotal role in the molecular regulation of multiple organ systems, including reproductive function and specifically uterine implantation and uterine pathophysiological conditions. Unfortunately, beyond these limited studies, there is no information on the expression and regulation of miRNAs in the uterus and more importantly the potential role of miRNA control of early and late phase estrogen responses in vivo. As such, the objective of the current study was to examine uterine expression of miRNAs in response to estrogen treatment during the early and late response phases within the mouse uterus.
Materials and Methods

Animals and Treatments
Mature female mice (CD1; Harlan, Indianapolis, IN, USA) were ovariectomized, rested 2 weeks, and treated subcutaneously (sc) with either estradiol 17-b (E 2 ; 10 mg/kg body weight [BW]) or sesame seed oil vehicle and sacrificed 2, 4, 8, 16, 24, or 30 hours after treatment administration. Uteri were removed and stored in RNalater (Ambion, Austin, TX, USA) until processed for RNA isolation.
A second study was conducted to examine whether the E 2 regulation of uterine miRNAs was mediated via its cognate nuclear receptor. To do so, mice were injected sc with ER antagonist ICI-182 780 (ICI; Tocris Cookson Inc, Ellisville, Missouri) 30 minutes before steroidal treatment. Estradiol was again administered, mice were sacrificed 8 hours post steroid administration, and tissues were processed as described above. We selected the 8-hour time point as this was shown to be a time after E 2 administration for maximal change in the level of expression for each examined miRNA.
MicroRNA Microarray Analysis
Uterine tissue was pooled from 3 mice per 0-, 2-, 4-, and 8-hour time points and from 2 mice per 16-, 24-and 30-hour time points. A total of 3 pools for each of the 7 time points (N ¼ 3/time point) were analyzed by miRNA microarray analysis (a total of 21 arrays). Total RNA was isolated from uterine tissue pools using miRNEasy columns according to the recommendations of the manufacturer (Qiagen, Valencia, California). Small RNA isolation and hybridization were performed by LC Sciences (Houston, Texas) using 5 to 10 mg of total RNA. Briefly, small RNA species were isolated from total RNA by column exclusion. The concentrated small RNAs were 3 0 -polyadenylated with poly(A) polymerase. A nucleotide tag was then ligated to the poly(A) tails. The tagged RNAs were hybridized to a mParaflo superfluidic array chip (miRBase version 10.0, www.miRBase.org) containing probes for 568 murine miRNA sequences as well as controls. Tagged RNA was subsequently labeled in a second hybridization reaction with Cy5 dendrimer dye. After overnight hybridization, arrays were stringently washed and scanned on an Axon GenePix 4000B laser scanner (Molecular Devices, Sunnyvale, California). Data extraction, imaging, and statistical analysis were performed by LC Sciences using ArrayPro software (Media Cybernetics, Bethesda, Maryland). After signal amplification, the background was subtracted and normalized using LOWESS (locally weighted regression) method. For a transcript to be listed as detectable, it had to meet the following criteria: signal intensity higher than 3Â (background SD), spot coefficient of variation <0.5 (coefficient of variation ¼ SD/signal intensity), and signals from at least 50% of the repeating probes above detection level. The array output was received in Excel spreadsheets as lists of raw data and also as ''simple detectable'' data, which were the average of 6 signal values for each miRNA on the array. For each set at each time point analyzed, significant differences (probability values) among groups for a given detectable miRNA signal were calculated. Those with P .05 were analyzed using gene hierarchical clustering of the log 2 value of each signal. Three separate analyses for each time point using different aliquots derived from independent pools of uterine tissue were used. A list of miRNAs from combined data from the 3 trials that showed significant differences across time (as determined by LC Sciences; >1.5-fold difference in expression and level of expression >1000 signal intensity [scale of 1 to 100 000 based on its fluorescence, which is indicative of its relative level within the tissue]) was generated. Of those, we selected a subset of miRNAs for verification by quantitative real-time reverse transcriptase polymerase chain reaction (qRT-PCR).
Quantitative Real-Time RT-PCR for miRNA
Quantitative RT-PCR was performed 30 to analyze the temporal expression and treatment effects of specific mature miRNAs. Total RNA was used from the same aliquots analyzed by microarrays (described above) or total RNA was isolated from additional samples using the same methodology as described under microarray analysis. MicroRNA kits for mirn99b, mirn181b, mirn429, and mirn451 were purchased from Applied Biosystems (Foster City, California) to quantitate their fold change in expression. Total RNA (250 ng in 5mL) was reverse transcribed using reverse transcription (RT) kits (Applied Biosystems) following the manufacturer's protocol with the following modifications. Briefly, miRNAs were reverse transcribed in a single reaction using 2 mL of each miRNA specific 5X RT primers. Resulting material was then used for independent qRT-PCR for each miRNA. To normalize for starting material, a reverse small nuclear RNA (snRNA) U6 was included in the miRNA RT reactions and qRT-PCR of U6 was performed. Quantitative RT-PCR reactions were completed on a 7900 HT Sequence Detection System (Applied Biosystems). Samples were run in triplicate and the average value used in subsequent calculations. Each primer set included a minus RT control. The 2-delta-delta CT method was used to calculate the fold-change values among samples. 31 Experiments were performed on at least 4 different independent replicates (N > 4) and data are displayed as the mean + standard deviation of the means (SD).
Statistical Analysis
Unless otherwise indicated, all data were analyzed by 1-way analysis of variance (ANOVA) for comparison across time points. When an F test indicated statistical significance, post hoc analysis was made using the Tukey HSD procedure. Unpaired t tests were used for planned comparisons between specific treatment groups within time points. Significance was set at P < .05 for all comparisons.
Results
Analysis of uterine miRNA expression (N ¼ 3 separate array analyses for each time point) revealed that of the 568 murine miRNAs analyzed, 445 were detectable in uterine tissue. Of these, 10 miRNAs were shown to be significantly regulated by E2 (Table 1) . From these, we selected 7 miRNAs (mirn429, mirn451, mirn99b, mirn181b, mirn204, mirn155, and mirn720) for further analysis based on their fold change in response to estrogen administration (>1.5-fold from controls). Table 2 summarizes the miRNA microarray data for those miRNAs whose expression significantly changed in response to estrogen administration. Expression of mirn155, mirn429, and mirn451 was significantly increased by estrogen administration whereas mirn181b and mirn204 expression was significantly reduced. To confirm the pattern of expression and fold changes compared to 0 hour controls, we performed qRT-PCR.
Quantitative RT-PCR confirmed for all analyzed miRNAs except for mirn99b and mirn720. Quantitative RT-PCR analysis failed to detect significant changes across time points for either of these miRNAs (data not shown). Similarly, we were unable to confirm the miRNA microarray-derived pattern of expression for mirn429 using qRT-PCR. However, we did detect significant decreases in mirn429 expression using this approach ( Figure 1A ). More specifically, mirn429 expression significantly decreased at 4 hours post estrogen administration and remained suppressed up to and including 30 hours post steroid treatment ( Figure 1A) . To determine whether the decrease in mirn429 expression in response to estrogen treatment was mediated via the cognate ER pathway, we pretreated the animals with the ER antagonist ICI 182 780 (ICI). As depicted in Figure 1B , pretreatment with ICI blocked the estrogen decrease in mirn429 expression and ICI alone had no affect on expression of the miRNA.
Assessment of mirn155 by qRT-PCR (Figure 2A ) revealed a similar pattern as detected by the microarray analysis ( Table 2) . More specifically, estrogen induced a modest but significant increase between 2 and 8 hours post estrogen administration and a more robust increase at 24 and 30 hours (Figure 2A ). This estrogen-induced increase in mirn155 expression was confirmed to occur via the ER pathway as ICI blocked the estrogen-induced increase in the expression of this miRNA ( Figure 2B ). ICI alone significantly reduced the expression of mirn155 ( Figure 2B) .
Of all the uterine miRNAs studied, mirn451 exhibited the most dramatic estrogen regulation, with peak expression occurring between 8 and 16 hours post estrogen administration ( Table 2 and Figure 3A ). The increase in mirn451 expression in response to estrogen administration was confirmed to occur via the ER pathway as ICI blocked the estrogen-induced increase in mirn451 expression ( Figure  3B ). ICI alone had no significant effect on expression of this miRNA ( Figure 3B ).
Based on our initial miRNA microarray analysis, mirn181b was the most significantly downregulated miRNAs ( Table 2) . This reduction was confirmed by qRT-PCR analysis ( Figure 4A ). In response to estrogen administration, mirn181b levels began to significantly decline 4 hours post steroid administration and remained suppressed through all time points. This decrease in mirn181b expression was confirmed to occur via the cognate ER pathway as ICI blocked the ability of this steroid to suppress mirn181b expression ( Figure 4B ). ICI alone had no impact on mirn181b expression.
Mirn204 expression was also decreased by estrogen administration with initial microarray analysis indicating that this regulation may be biphasic ( Table 2 ). Quantitative RT-PCR analysis confirmed that mirn204 expression was reduced in response to estrogen administration, but we could not duplicate this biphasic pattern ( Figure 5A ). We did find that mirn204 expression was significantly reduced at 2 hours post estrogen administration, continued to decline after this time point and remained significantly reduced at 30 hours post steroid administration ( Figure 5A ). The estrogen-imparted decrease in mirn204 expression was confirmed to occur via the ER pathway as ICI blocked the estrogen decrease in mirn204 expression ( Figure 5A ). However, much like that of mirn155 ( Figure 2B ), ICI alone significantly reduced the expression of uterine mirn204 expression ( Figure 5B ).
Discussion
In the current study we demonstrate for the first time that estrogen regulates the expression of a subset of miRNAs within the murine uterus. Estrogen regulation of some of these miRNAs can be blocked by the ER antagonist ICI 182 780, indicating modulation via the classical ERs-dependent pathway. In contrast, expression of other miRNAs was directly modulated by ICI 182 780 itself, which may suggest modulation via ERindependent pathways. The major estrogen-regulated uterine murine miRNAs were mirn429, mirn155, mirn451, mirn181b, and mirn204. MicroRNAs have been proposed to play a role in modulating posttranscriptional gene regulation within the uterus. 18 With respect to the impact of steroidal regulation on endometrial miRNA expression, studies have been limited to descriptive studies utilizing endometrial biopsies. One study that solely examined the expression of miRNAs in endometrial biopsies from ''normal'' reproductive cycling patients was conducted by Kuokkanen and colleagues. 20 In this study, the genomic profiling of miRNAs of human endometrium epithelial cells revealed that a set of 12 miRNAs were differentially expressed between late proliferative and midsecretory specimens. Of those 12, we could only confirm the expression and similar regulation of 1 miRNA, that being mirn204. In human endometrium epithelium, mirn204 (MIR204) was lower in the proliferative specimens compared to the secretory and would suggest a downregulation by estrogen, which is consistent with our findings.
In addition to the study by Kuokkanen and colleagues, 20 several reports have been published, which have focused on identifying miRNAs that may be expressed in uterine disease such as endometriosis 19, [22] [23] [24] [25] [26] and endometrial cancer. [27] [28] [29] One of the first studies to profile miRNA expression between endometrium from women with and without endometriosis was conducted by Pan and colleagues. 26 Forty-eight miRNAs were differentially expressed among eutopic and ectopic endometrium from women with versus endometrium from women without the disease. Of this group, mirn451 was one of the most significantly reduced miRNAs in ectopic and eutopic endometrium from women with endometriosis. Although endometriosis is considered an estrogen-dependent disease, this pattern of expression is in contrast to that detected in our current study, where murine uterine mirn451 expression was significantly increased by estrogen.
The finding that mirn451 expression is reduced in ectopic and eutopic endometrium from women with endometriosis may be of great clinical interest. mirn451 has been proposed to regulate cell proliferation via regulation of macrophage migration inhibitory factor (MIF) 32 and is also a putative regulator of MMP3 and MYC (TargetScanHuman 5.1, www.targetscan.org), both of which are overexpressed in endometriosis. [33] [34] [35] [36] Collectively, reduced expression of mirn451may allow for a posttranscriptional mis-regulation of these factors which in turn contributes to the pathophysiology of endometriosis.
Four other miRNAs were identified as being estrogen regulated in our current study, mirn429, mirn155, mirn204, and mirn181b. Our current data demonstrate that in response to estrogen, murine uterine expression of mirn429 is significantly downregulated. mirn429 downregulation has been associated with mesenchymal to epithelial transition, 37 but its role and relevant target transcripts in uterine tissue remain unknown.
Mirn155 is perhaps the most well studied of all miRNAs. Relative to the current study, mirn155 has been proposed to function as a protective miRNA that may locally downregulate the expression of matrix metalloproteinases. 38 As such, it is tempting to speculate that mirn155 may fine-tune the estrogen regulation of this system under normal physiological conditions within the endometrium, 39 whereas mis-expression of mirn155 may lead to abnormal expression of matrix metalloproteinases.
In the current study, both mirn204 and mirn181b expression was decreased by estrogen administration. Mirn204 was originally isolated from the eye 40 and more recently its role in cancers of epithelial cell origin was reported. 41 In this study by Lee and colleagues, 41 mirn204 expression was reduced in 50% of the various types of cancers compared to controls. Endometrial cancer was one of the types of cancer in which mirn204 expression did not differ. Although this observation would suggest that mirn204 mis-expression may not contribute to the pathology of endometrial carcinoma, it does not rule out the possibility that this miRNA may regulate important estrogen-regulated targets within the endometrium such as matrix metalloproteinase 9 (MMP-9). The pattern of MMP-9 expression in the mouse uterus described in our previous work 42, 43 coupled with the current observation that mirn204 is reduced in response to estrogen administration would suggest that this miRNA may regulate uterine MMP-9 expression.
To the best of our knowledge, our study is the first to describe the uterine expression of mirn181b. In our study, uterine expression of mirn181b was decreased by estrogen administration.
Mirn181b was first described as being downregulated in glioblastoma 44 and since has been associated with leukemia and various forms of cancer. [45] [46] [47] [48] Of relevance to the current study is that mirn181b is a putative regulator of tissue inhibitor of metalloproteinase 3 (TIMP-3, which regulates MMP-9 activity) and that estrogen induction of uterine TIMP3 49 is inversely correlated with mirn181b (and mirn204) expression. These observations make it interesting to speculate that within the mouse uterus estrogen may regulate this important proteaseÀprotease inhibitor system via these miRNAs.
In addition to the in vivo profiling of endometrial miRNAs, in vitro studies using isolated endometrial stromal and epithelial cells have been conducted to examine steroidal regulation of select miRNAs. 23, 26 These studies demonstrated that endometrial stromal and/or epithelial cell miRNA expression could be modulated by estrogen and that in some cases this modulation could be blocked by the ER antagonist 182 780 ICI (ICI). These studies also demonstrated that for some miRNAs, ICI alone acted as an estrogen agonist to either increase or decrease the expression of these miRNAs. These observations are in agreement with those in the current study where in vivo administration of ICI alone resulted in significant reductions in mirn155 and mirn204. The ability of ICI to act independent of estrogen has been reported in MCF-7 breast cancer cells. [50] [51] [52] One mechanism that may explain the ability of ICI to downregulate gene expression and/or miRNA expression (current study as well as those by Pan and colleagues 26 and Toloubeydokhti and coworkers 23 ) is that ICI can decrease protein levels of ER which in turn may suppress potential ligand-independent activity of the ER. 52 Further analysis will be required to thoroughly dissect the mechanisms by which the ER pathway regulates the transcription of miRNAs.
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